Details of the Drug

General Information of Drug (ID: DM5PU6O)

Drug Name
Oxcarbazepine
Synonyms
Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 252.27
Topological Polar Surface Area (xlogp) 1.7
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 34 micromol/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4.5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
95% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The clearance of drug is 84.9 L/h [6]
Elimination
Following oral administration, more than 95% of the administered dose of oxcarbazepine is found in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [3]
Metabolism
The drug is metabolized via reduction by several members of the aldo-keto reductase family of cytosolic liver enzymes [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 135.9034 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 49 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.085 mg/mL [4]
Chemical Identifiers
Formula
C15H12N2O2
IUPAC Name
5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
Canonical SMILES
C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
InChI
InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
InChIKey
CTRLABGOLIVAIY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
34312
ChEBI ID
CHEBI:7824
CAS Number
28721-07-5
DrugBank ID
DB00776
TTD ID
D0QL3P
VARIDT ID
DR00453
INTEDE ID
DR1744
ACDINA ID
D00500

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Blocker [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Oxcarbazepine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Zonisamide DM0DTF7 Moderate Increased metabolism of Oxcarbazepine caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Primidone DM0WX6I Moderate Increased metabolism of Oxcarbazepine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Tiagabine DMKSQG0 Moderate Increased metabolism of Oxcarbazepine caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Stiripentol DMMSDOY Moderate Increased metabolism of Oxcarbazepine caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Oxcarbazepine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Clonazepam DMTO13J Moderate Increased metabolism of Oxcarbazepine caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Phenobarbital DMXZOCG Moderate Increased metabolism of Oxcarbazepine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Oxcarbazepine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Oxcarbazepine and Methylene blue. Acquired methaemoglobinaemia [3A93] [30]
Repaglinide DM5SXUV Moderate Increased metabolism of Oxcarbazepine caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [31]
Pioglitazone DMKJ485 Moderate Increased metabolism of Oxcarbazepine caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [28]
Midostaurin DMI6E0R Moderate Increased metabolism of Oxcarbazepine caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Oxcarbazepine caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [33]
Oliceridine DM6MDCF Major Increased metabolism of Oxcarbazepine caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [34]
Donepezil DMIYG7Z Moderate Increased metabolism of Oxcarbazepine caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [28]
Ivabradine DM0L594 Moderate Increased metabolism of Oxcarbazepine caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [29]
Bepridil DM0RKS4 Moderate Increased metabolism of Oxcarbazepine caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Dronedarone DMA8FS5 Moderate Increased metabolism of Oxcarbazepine caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [35]
Nifedipine DMSVOZT Moderate Increased metabolism of Oxcarbazepine caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Bedaquiline DM3906J Moderate Increased metabolism of Oxcarbazepine caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [36]
Cilostazol DMZMSCT Moderate Decreased metabolism of Oxcarbazepine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [37]
Clarithromycin DM4M1SG Moderate Increased metabolism of Oxcarbazepine caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Telithromycin DMZ4P3A Moderate Increased metabolism of Oxcarbazepine caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Cariprazine DMJYDVK Moderate Increased metabolism of Oxcarbazepine caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [29]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Oxcarbazepine caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Lapatinib DM3BH1Y Moderate Increased metabolism of Oxcarbazepine caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Exemestane DM9HPW3 Moderate Increased metabolism of Oxcarbazepine caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Oxcarbazepine caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Tucatinib DMBESUA Moderate Increased metabolism of Oxcarbazepine caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Palbociclib DMD7L94 Moderate Increased metabolism of Oxcarbazepine caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Alpelisib DMEXMYK Moderate Increased metabolism of Oxcarbazepine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Letrozole DMH07Y3 Moderate Increased metabolism of Oxcarbazepine caused by Letrozole mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Oxcarbazepine caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Oxcarbazepine caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Moderate Increased metabolism of Oxcarbazepine caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Estradiol DMUNTE3 Moderate Increased metabolism of Oxcarbazepine caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Atorvastatin DMF28YC Moderate Increased metabolism of Oxcarbazepine caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [46]
Macitentan DMP79A1 Moderate Increased metabolism of Oxcarbazepine caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [47]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Oxcarbazepine caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [48]
PF-04449913 DMSB068 Moderate Increased metabolism of Oxcarbazepine caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [49]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Oxcarbazepine caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [28]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Oxcarbazepine when combined with Levomilnacipran. Chronic pain [MG30] [50]
Drospirenone DM1A9W3 Major Increased metabolism of Oxcarbazepine caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [41]
Levonorgestrel DM1DP7T Major Increased metabolism of Oxcarbazepine caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [41]
Ulipristal DMBNI20 Moderate Increased metabolism of Oxcarbazepine caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [29]
Norgestimate DMYP4XC Major Increased metabolism of Oxcarbazepine caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [51]
Levobupivacaine DM783CH Minor Increased metabolism of Oxcarbazepine caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [52]
Halothane DM80OZ5 Moderate Increased metabolism of Oxcarbazepine caused by Halothane mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [28]
Cocaine DMSOX7I Moderate Increased metabolism of Oxcarbazepine caused by Cocaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [28]
Alfentanil DMVO0UB Moderate Increased metabolism of Oxcarbazepine caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [53]
Mifepristone DMGZQEF Moderate Increased metabolism of Oxcarbazepine caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [54]
Osilodrostat DMIJC9X Moderate Increased metabolism of Oxcarbazepine caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [55]
Ivacaftor DMZC1HS Moderate Increased metabolism of Oxcarbazepine caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [56]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Oxcarbazepine and Ethanol. Cystitis [GC00] [57]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Oxcarbazepine caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [58]
Sertraline DM0FB1J Moderate Antagonize the effect of Oxcarbazepine when combined with Sertraline. Depression [6A70-6A7Z] [50]
Vilazodone DM4LECQ Moderate Antagonize the effect of Oxcarbazepine when combined with Vilazodone. Depression [6A70-6A7Z] [50]
Nefazodone DM4ZS8M Moderate Increased metabolism of Oxcarbazepine caused by Nefazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [28]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Oxcarbazepine and Selegiline. Depression [6A70-6A7Z] [30]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Oxcarbazepine when combined with Vortioxetine. Depression [6A70-6A7Z] [50]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Oxcarbazepine and Isocarboxazid. Depression [6A70-6A7Z] [30]
Milnacipran DMBFE74 Moderate Antagonize the effect of Oxcarbazepine when combined with Milnacipran. Depression [6A70-6A7Z] [50]
Escitalopram DMFK9HG Moderate Decreased metabolism of Oxcarbazepine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [59]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Oxcarbazepine and Desvenlafaxine. Depression [6A70-6A7Z] [50]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Oxcarbazepine and Phenelzine. Depression [6A70-6A7Z] [30]
Clomipramine DMINRKW Moderate Decreased metabolism of Oxcarbazepine caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [34]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Oxcarbazepine and Esketamine. Depression [6A70-6A7Z] [34]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Oxcarbazepine caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [60]
Oxybutynine DMJPBAX Moderate Increased metabolism of Oxcarbazepine caused by Oxybutynine mediated induction of CYP450 enzyme. Discovery agent [N.A.] [28]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Oxcarbazepine caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [51]
Praziquantel DMOU1PK Moderate Increased metabolism of Oxcarbazepine caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [61]
Bay 80-6946 DMLOS5R Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [62]
Tazemetostat DMWP1BH Moderate Increased metabolism of Oxcarbazepine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [63]
Solifenacin DMG592Q Moderate Increased metabolism of Oxcarbazepine caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [64]
Mirabegron DMS1GYT Minor Increased metabolism of Oxcarbazepine caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [65]
Tolterodine DMSHPW8 Moderate Increased metabolism of Oxcarbazepine caused by Tolterodine mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [28]
Itraconazole DMCR1MV Moderate Increased metabolism of Oxcarbazepine caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Ketoconazole DMPZI3Q Moderate Increased metabolism of Oxcarbazepine caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Oxcarbazepine caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [34]
Sunitinib DMCBJSR Moderate Increased metabolism of Oxcarbazepine caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [34]
Avapritinib DMK2GZX Moderate Increased metabolism of Oxcarbazepine caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [29]
Boceprevir DMBSHMF Moderate Increased metabolism of Oxcarbazepine caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [66]
PSI-7977 DMLSUWZ Major Accelerated clearance of Oxcarbazepine due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [34]
Simeprevir DMLUA9D Major Increased metabolism of Oxcarbazepine caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [67]
Telaprevir DMMRV29 Moderate Increased metabolism of Oxcarbazepine caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [66]
Rifampin DMA8J1G Moderate Increased metabolism of Oxcarbazepine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [68]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Oxcarbazepine and Procarbazine. Hodgkin lymphoma [2B30] [30]
MK-1439 DM215WE Major Increased metabolism of Oxcarbazepine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Fostemsavir DM50ILT Minor Increased metabolism of Oxcarbazepine caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Cobicistat DM6L4H2 Moderate Increased metabolism of Oxcarbazepine caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Tipranavir DM8HJX6 Moderate Increased metabolism of Oxcarbazepine caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Dolutegravir DMCZGRE Major Increased metabolism of Oxcarbazepine caused by Dolutegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [34]
Saquinavir DMG814N Moderate Increased metabolism of Oxcarbazepine caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Elvitegravir DMG9B1U Moderate Increased metabolism of Oxcarbazepine caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [34]
Etravirine DMGV8QU Moderate Increased metabolism of Oxcarbazepine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Rilpivirine DMJ0QOW Major Increased metabolism of Oxcarbazepine caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Darunavir DMN3GCH Moderate Increased metabolism of Oxcarbazepine caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Atazanavir DMSYRBX Moderate Increased metabolism of Oxcarbazepine caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
GSK1265744 DMT8J0I Major Increased metabolism of Oxcarbazepine caused by GSK1265744 mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [74]
Maraviroc DMTL94F Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [34]
Paricalcitol DMYBV3G Moderate Increased metabolism of Oxcarbazepine caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [48]
Levamlodipine DM92S6N Moderate Increased metabolism of Oxcarbazepine caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Felodipine DMOSW35 Moderate Increased metabolism of Oxcarbazepine caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Tolvaptan DMIWFRL Moderate Increased metabolism of Oxcarbazepine caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [29]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Oxcarbazepine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [29]
Suvorexant DM0E6S3 Moderate Increased metabolism of Oxcarbazepine caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
Triazolam DMETYK5 Moderate Increased metabolism of Oxcarbazepine caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Oxcarbazepine caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [76]
ITI-007 DMUQ1DO Major Increased metabolism of Oxcarbazepine caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [77]
Quazepam DMY4D87 Moderate Decreased metabolism of Oxcarbazepine caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [34]
Estazolam DMZGXUM Moderate Increased metabolism of Oxcarbazepine caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Naloxegol DML0B41 Moderate Increased metabolism of Oxcarbazepine caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [78]
Pemigatinib DM819JF Moderate Increased metabolism of Oxcarbazepine caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [29]
Crizotinib DM4F29C Moderate Increased metabolism of Oxcarbazepine caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [74]
Brigatinib DM7W94S Moderate Increased metabolism of Oxcarbazepine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [34]
Ceritinib DMB920Z Moderate Increased metabolism of Oxcarbazepine caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Osimertinib DMRJLAT Moderate Increased metabolism of Oxcarbazepine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Capmatinib DMYCXKL Moderate Increased metabolism of Oxcarbazepine caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [81]
Artemether DM48QOT Moderate Increased metabolism of Oxcarbazepine caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [34]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Oxcarbazepine when combined with Hydroxychloroquine. Malaria [1F40-1F45] [34]
Idelalisib DM602WT Moderate Increased metabolism of Oxcarbazepine caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
GDC-0199 DMH0QKA Moderate Increased metabolism of Oxcarbazepine caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
IPI-145 DMWA24P Moderate Increased metabolism of Oxcarbazepine caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Oxcarbazepine caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [85]
Ibrutinib DMHZCPO Moderate Increased metabolism of Oxcarbazepine caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ponatinib DMYGJQO Moderate Increased metabolism of Oxcarbazepine caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [34]
Vemurafenib DM62UG5 Moderate Increased metabolism of Oxcarbazepine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [87]
Selumetinib DMC7W6R Moderate Increased metabolism of Oxcarbazepine caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [88]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Oxcarbazepine caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [51]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Oxcarbazepine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [89]
Ubrogepant DM749I3 Moderate Increased metabolism of Oxcarbazepine caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [90]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Oxcarbazepine and Lasmiditan. Migraine [8A80] [91]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Oxcarbazepine caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [48]
Panobinostat DM58WKG Moderate Increased metabolism of Oxcarbazepine caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [92]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Oxcarbazepine and Thalidomide. Multiple myeloma [2A83] [93]
Nilotinib DM7HXWT Moderate Increased metabolism of Oxcarbazepine caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [94]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Oxcarbazepine caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [95]
Dasatinib DMJV2EK Moderate Increased metabolism of Oxcarbazepine caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [34]
Busulfan DMXYJ9C Moderate Increased metabolism of Oxcarbazepine caused by Busulfan mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Rolapitant DM8XP26 Moderate Increased metabolism of Oxcarbazepine caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [96]
Ondansetron DMOTQ1I Moderate Increased metabolism of Oxcarbazepine caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [28]
E-2007 DMJDYNQ Moderate Increased metabolism of Oxcarbazepine caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [29]
Entrectinib DMMPTLH Moderate Increased metabolism of Oxcarbazepine caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [97]
Sibutramine DMFJTDI Moderate Increased metabolism of Oxcarbazepine caused by Sibutramine mediated induction of CYP450 enzyme. Obesity [5B80-5B81] [28]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Oxcarbazepine caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [68]
Olaparib DM8QB1D Moderate Increased metabolism of Oxcarbazepine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [34]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Oxcarbazepine and Buprenorphine. Pain [MG30-MG3Z] [98]
Hydrocodone DMQ2JO5 Major Increased metabolism of Oxcarbazepine caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [34]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Oxcarbazepine and Rasagiline. Parkinsonism [8A00] [30]
Pimavanserin DMR7IVC Moderate Increased metabolism of Oxcarbazepine caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [99]
Bromocriptine DMVE3TK Moderate Increased metabolism of Oxcarbazepine caused by Bromocriptine mediated induction of CYP450 enzyme. Parkinsonism [8A00] [28]
Macimorelin DMQYJIR Moderate Increased metabolism of Oxcarbazepine caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [100]
Lefamulin DME6G97 Moderate Increased metabolism of Oxcarbazepine caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [101]
Ergonovine DM0VEC1 Moderate Increased metabolism of Oxcarbazepine caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [34]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Oxcarbazepine caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [102]
Enzalutamide DMGL19D Moderate Increased metabolism of Oxcarbazepine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [103]
Darolutamide DMV7YFT Moderate Increased metabolism of Oxcarbazepine caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [104]
Silodosin DMJSBT6 Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [34]
Apremilast DMTWS9E Moderate Increased metabolism of Oxcarbazepine caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [105]
Riociguat DMXBLMP Moderate Increased metabolism of Oxcarbazepine caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [106]
Everolimus DM8X2EH Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Everolimus. Renal cell carcinoma [2C90] [34]
Axitinib DMGVH6N Moderate Increased metabolism of Oxcarbazepine caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [107]
Temsirolimus DMS104F Moderate Increased metabolism of Oxcarbazepine caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [34]
Tofacitinib DMBS370 Moderate Increased metabolism of Oxcarbazepine caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [34]
Dexamethasone DMMWZET Moderate Increased metabolism of Oxcarbazepine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [28]
Quetiapine DM1N62C Moderate Increased metabolism of Oxcarbazepine caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [34]
Aripiprazole DM3NUMH Moderate Increased metabolism of Oxcarbazepine caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [108]
Fentanyl DM8WAHT Major Increased metabolism of Oxcarbazepine caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [34]
Avanafil DM75CXN Moderate Increased metabolism of Oxcarbazepine caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [109]
Tadalafil DMJZHT1 Moderate Increased metabolism of Oxcarbazepine caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [29]
LDE225 DMM9F25 Moderate Increased metabolism of Oxcarbazepine caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [110]
Larotrectinib DM26CQR Moderate Increased metabolism of Oxcarbazepine caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [34]
Methylprednisolone DM4BDON Moderate Increased metabolism of Oxcarbazepine caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Ifosfamide DMCT3I8 Moderate Increased metabolism of Oxcarbazepine caused by Ifosfamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Docetaxel DMDI269 Moderate Increased metabolism of Oxcarbazepine caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Trabectedin DMG3Y89 Moderate Increased metabolism of Oxcarbazepine caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Armodafinil DMGB035 Moderate Increased metabolism of Oxcarbazepine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [112]
LEE011 DMMX75K Moderate Increased metabolism of Oxcarbazepine caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [34]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Oxcarbazepine caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Taxol DMUOT9V Moderate Increased metabolism of Oxcarbazepine caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [113]
Doxorubicin DMVP5YE Moderate Increased metabolism of Oxcarbazepine caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Fostamatinib DM6AUHV Moderate Increased metabolism of Oxcarbazepine caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [114]
Apixaban DM89JLN Moderate Increased metabolism of Oxcarbazepine caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [115]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Oxcarbazepine caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [116]
Sirolimus DMGW1ID Moderate Increased metabolism of Oxcarbazepine caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [34]
Saxagliptin DMGXENV Moderate Increased metabolism of Oxcarbazepine caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [117]
Linagliptin DMWFJTR Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Linagliptin. Type 2 diabetes mellitus [5A11] [118]
Elagolix DMB2C0E Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Elagolix. Uterine fibroid [2E86] [119]
Betrixaban DM2C4RF Moderate Accelerated clearance of Oxcarbazepine due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [120]
Amiodarone DMUTEX3 Moderate Increased metabolism of Oxcarbazepine caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [28]
⏷ Show the Full List of 182 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Meglumine E00181 8567 Buffering agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 2000 E00649 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Oxcarbazepine 300 mg tablet 300 mg 24 HR Extended Release Oral Tablet Oral
Oxcarbazepine 150 mg tablet 150 mg 24 HR Extended Release Oral Tablet Oral
Oxcarbazepine 600 mg tablet 600 mg 24 HR Extended Release Oral Tablet Oral
Oxcarbazepine 150 mg tablet 150 mg Oral Tablet Oral
Oxcarbazepine 300 mg tablet 300 mg Oral Tablet Oral
Oxcarbazepine 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7254).
2 Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
3 DailyMed Label: TRILEPTAL (oxcarbazepine) film-coated tablets or suspension, for oral use
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Antunes NJ, van Dijkman SC, Lanchote VL, Wichert-Ana L, Coelho EB, Alexandre Junior V, Takayanagui OM, Tozatto E, van Hasselt JGC, Della Pasqua O: Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci. 2017 Nov 15;109S:S116-S123. doi: 10.1016/j.ejps.2017.05.034. Epub 2017 May 17.
7 Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
10 Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47.
11 The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
12 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
13 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
16 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
17 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
18 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
19 Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
20 The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
21 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
22 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
23 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
24 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
25 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
26 Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
27 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
28 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
29 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
31 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
32 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
33 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
34 Cerner Multum, Inc. "Australian Product Information.".
35 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
36 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
37 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
38 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
39 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
40 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
41 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
42 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
43 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
45 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
47 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
48 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
49 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
51 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
52 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
53 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
54 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
55 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
56 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
57 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
58 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
59 Canadian Pharmacists Association.
60 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
61 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
62 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
63 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
64 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
65 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
66 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
67 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
68 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
69 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
70 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
71 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
72 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
73 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
74 Cerner Multum, Inc. "Canadian Product Information.".
75 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
76 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
77 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
78 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
83 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
84 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
85 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
87 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
88 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
90 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
92 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
94 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
95 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
96 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
97 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
98 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
99 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
100 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
101 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
102 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
103 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
104 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
105 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
106 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
107 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
108 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
109 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
110 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
111 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
112 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
113 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
114 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
115 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
116 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
117 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
118 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
119 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
120 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]